Comparative Pharmacology
Head-to-head clinical analysis: SCOPOLAMINE versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SCOPOLAMINE versus VESICARE.
SCOPOLAMINE vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category A/B
Category C
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."